Company news
Inoviq Ltd (ASX:IIQ) news
Inoviq Ltd news releases on 6ix. Latest, Sep 29, 2026: EXO-OC Technical Review and Commercialisation Pathway
Press releases & updates
EXO-OC Technical Review and Commercialisation Pathway
September 29, 2026
EXO-OC Study Outcome Investor Webinar Presentation
July 13, 2026
Quarterly Activities Report and Appendix 4C - June 2026
July 12, 2026
EXO-OC algorithm and clinical study update
June 30, 2026
Positive CAR-exosome data in ovarian cancer
June 24, 2026
Quarterly Activities Report and Appendix 4C - March 2026
April 27, 2026
Appendix 4D and FY26 Half Year Financial Report
February 17, 2026
Quarterly Business Update and Appendix 4C - December 2025
January 28, 2026
Positive in vivo CAR-EV data in TNBC
December 21, 2025
Quarterly Business Update and Appendix 4C - September 2025
October 28, 2025
IIQ completes placement and lodges SPP Offer Booklet
October 16, 2025
Investor Presentation
October 12, 2025
INOVIQ completes $9.5m placement
October 12, 2025
Trading Halt
October 8, 2025
IIQ Licences worldwide OC Biomarker IP from UniQuest
September 26, 2025
CAR-NK EVs kill Breast Cancer Cells in vitro at Peter Mac
September 22, 2025
Appendix 4E and Preliminary Financial Report
August 22, 2025
Quarterly Business Update and Appendix 4C - June 2025
July 30, 2025
INOVIQ Investor Webinar Presentation Slides
July 14, 2025
Response to ASX Query
June 23, 2025
New treatment kills 88% of Breast and Lung Cancer cells
June 17, 2025
Reinstatement to Official Quotation
June 2, 2025
Early Ovarian Cancer Screening Breakthrough
June 2, 2025
Suspension from Quotation
May 28, 2025
Response to ASX Price Query
May 27, 2025
Pause in Trade
May 26, 2025
Quarterly Business Update and Appendix 4C - March 2025
April 29, 2025
Appendix 4D and FY25 Half Year Financial Report
February 20, 2025
Quarterly Business Update and Appendix 4C - December 2024
January 30, 2025
Weaponising Exosomes for Breast Cancer treatment
December 15, 2024
Disease Specificity study completed for NeuCA15-3 test
December 4, 2024
EXO-OC test delivers outstanding performance
December 2, 2024
AGM CEO Presentation
November 27, 2024
INOVIQ receives $1m RDTI refund
November 25, 2024
Quarterly Business Update and Appendix 4C - September 2024
October 30, 2024
NEURO-NET validated in Parkinson's
August 19, 2024
Quarterly Activities Report and Appendix 4C - June 2024
July 29, 2024
Successful completion of Share Purchase Plan
July 4, 2024
INOVIQ lodges SPP and Options Prospectus
June 18, 2024
INOVIQ isolates brain-derived exosomes in Alzheimer's
June 12, 2024
INOVIQ completes $7m placement
June 12, 2024
Breakthrough Exosome Therapy
June 2, 2024
Quarterly Activities Report and Appendix 4C - March 2024
April 30, 2024
Ovarian Cancer Test Validation
April 18, 2024
INOVIQ Investor Update
April 17, 2024
INOVIQ and Promega sign Global EXO-NET Agreement
April 15, 2024
Appendix 4D and FY24 Half Year Financial Report
February 22, 2024
INOVIQ detects 19% more breast cancers than leading test
February 22, 2024
Appendix 4C and Quarterly Activities Report - December 2023
January 30, 2024
2023 AGM CEO Presentation
November 28, 2023